Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Alterity Therapeutics received FDA alignment on a registrational pathway for ATH434 in multiple system atrophy, with a single pivotal Phase 3 trial expected to support New Drug Application filing. The drug targets iron accumulation and alpha-synuclein pathology, with enrollment planned for late 2026.
AI care robots demonstrated measurable reductions in loneliness and depressive symptoms among isolated older adults in South Korea, with effectiveness sustained over a 12-week intervention period. The mechanism appears to involve both direct companionship and the initiation of human social contact through robot-facilitated engagement.
A year-long home-based study of 119 participants demonstrates that individuals with mild Alzheimer's disease can reliably self-administer frequent brain health assessments using a wireless EEG headset and cognitive task platform, achieving 99.7% completion rates and generating high-frequency data that may accelerate clinical trial design and reduce costs.
Annovis Bio has enrolled 850 patients with early Alzheimer's disease in a Phase 3 trial of Buntanetap, a daily oral therapeutic targeting pTau217 pathology. The dual-endpoint design will assess both symptomatic improvement at six months and disease-modifying effects at 18 months, with regulatory submissions anticipated in 2027-2028.
EyePoint Pharmaceuticals is advancing retinal disease treatment through clinical trials and new research presentations, with emphasis on early detection of wet age-related macular degeneration to prevent rapid symptom progression. The company's engagement with retinal specialists positions novel therapeutic approaches within the broader context of preserving vision-dependent functional capacity during aging.
Alterity Therapeutics has secured FDA alignment on a registrational pathway for ATH434, a candidate treatment for multiple system atrophy, with agreement on primary endpoints, dosing, and trial design based on Phase 2 efficacy data. This regulatory clarity positions the program for pivotal Phase 3 initiation by late 2026, addressing a neurodegenerative disease with no approved disease-modifying therapies.
NeuroSense is advancing PrimeC, a dual-mechanism oral therapy targeting neuroinflammation and oxidative stress in ALS, into Phase 3 trials after Phase 2b data demonstrated slowed disease progression and survival benefit. The compound addresses multiple pathological drivers simultaneously rather than targeting single endpoints, representing a shift in how neurodegenerative disease progression is being conceptualized and treated.
Integration of at-home EEG sleep monitoring into decentralized clinical trials enables objective measurement of sleep architecture with 88-96% agreement to laboratory polysomnography. This addresses a critical measurement gap in CNS studies where sleep quality directly influences neurological outcomes and therapeutic response.
Alzheimer's treatment is transitioning from single-target drug development toward multimodal approaches combining pharmacotherapy, neurotech, and regenerative medicine. AAIC 2026 reflects this shift, with emerging companies demonstrating that disease management now requires addressing multiple biological drivers simultaneously rather than pursuing one breakthrough intervention.
Biogen is repositioning its pipeline toward high-value biologic therapies in neurology and rare genetic diseases, aiming to establish durable revenue streams through specialist-driven commercialization and premium pricing in areas of significant unmet medical need. This strategy reflects a consolidation around conditions where targeted interventions can address specific molecular pathologies, potentially extending both lifespan and functional capacity in populations with otherwise progressive neurological decline.
AlzeCure licensed its NeuroRestore platform—including the clinical-stage candidate ACD856—to QuantumCell in a $2.2 billion deal structured to accelerate development of a neuroprotective agent designed to reduce neuroinflammation and slow Alzheimer's progression. The partnership model reflects growing commercial confidence in small-molecule approaches that target neurodegeneration through multiple pathways rather than single-target mechanisms.
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.